Pneumococcal LytA Autolysin, a Potent Therapeutic Agent in Experimental Peritonitis-Sepsis Caused by Highly β-Lactam-Resistant Streptococcus pneumoniae

New therapeutic strategies for combating infections caused by antibiotic-resistant Streptococcus pneumoniae are being sought. Lytic enzymes produced by bacteria and phages may be useful alternatives for the treatment of pneumococcal infections. The LytA amidase is the main pneumococcal autolysin (3, 6) and is responsible for the lytic effects of penicillin and other cell wall inhibitors (5, 10, 11). Cpl-1 is a lysozyme encoded by pneumococcal phage Cp-1 (1, 2, 4).

The aim of this study was to compare the in vitro and in vivo activities of purified LytA and Cpl-1 with those of cefotaxime (CTX) against a β-lactam-resistant (penicillin MIC, 2 μg/ml) meningeal pneumococcal isolate (strain MJD3693).

The MICs of LytA, Cpl-1, and CTX for strain MJD3693 were 16, 32, and 4 μg/ml, respectively, as determined by the broth microdilution methodology (7). LytA and Cpl-1 were overproduced and purified by affinity chromatography in DEAE-cellulose (8). One unit of enzymatic activity (5) was defined as the amount of enzyme that catalyzed the hydrolysis of 1 μg (∼715 net cpm) of [methyl-³H]choline-labeled pneumococcal cell walls (6) in 10 min at 37°C. Time-kill experiments were performed in three separate assays by exposing early-log-phase cultures of MJD3693 to 50 μg/ml of LytA, Cpl-1, or CTX in tubes with either cation-adjusted Mueller-Hinton broth with 4% lysed horse blood (CA-MHB-LHB) or phosphate-buffered saline (PBS; pH 7.0). Such a concentration was over 12-fold greater than the CTX MIC but only 1.6- and 3-fold higher than the MICs of Cpl-1 and LytA, respectively. After incubation at 35°C, the bacterial titers were compared at 1, 3, and 5 h (Table 1). The killing effects of the enzymes were very rapid and were similar in both media, and their antipneumococcal activities was remarkably higher than that of CTX, particularly in PBS. In CA-MHB-LHB at 1 and 3 h, LytA and Cpl-1 were significantly more effective than CTX (P ≤ 0.018), although after 5 h incubation, only LytA demonstrated a significantly higher activity than CTX (P = 0.004). In PBS, LytA and Cpl-1 exerted a profound bactericidal effect at all times, whereas, as expected, the effect of CTX in PBS was quite poor (Table 1).

The plasma pharmacokinetics of purified LytA and the in vivo efficacies of the compounds were studied by using adult Swiss mice, with the approval of the Fundación Jiménez Díaz Ethics Committee. The plasma pharmacokinetics of LytA were determined by using a solution of 3.1 mg/ml (specific activity, 5.9 × 10⁵ U/mg). After the administration of single intravenous (i.v.) doses (via the tail vein) of LytA (25 mg/kg) to uninfected mice, blood samples were obtained from three animals per group, which were killed at 5, 15, 60, and 120 min; and the plasma enzyme activity was measured. The mean plasma area under the enzymatic activity-time curve was 3,440 U·min·μl⁻¹, with an intercept value of 101 U/μl. The plasma half-life of LytA was 22.5 min, which was similar to that of Cpl-1 (20.5 min) (4) and longer than that of CTX (ca. 12 min) (9).

To induce the peritonitis-sepsis model, the mice were intraperitoneally (i.p.) inoculated with 0.25 ml of the pneumococcal suspension (7.3 ± 0.3 log₁₀ CFU per mouse). This inoculum was 100% lethal within 1 to 3 days and provided a detectable number of bacteria in the peritoneal cavity and blood. Treatments were started 1 h after bacterial challenge as single 0.25-ml doses by i.p. or i.v. administration. Ten groups of infected mice (five to six animals per group) were used; half of them were treated by each route. The mice were treated with LytA (1.7 mg; 57 mg/kg of body weight; specific activity, 8.9 × 10⁵ U/mg), Cpl-1 (1.4 mg; 47 mg/kg; specific activity, 9.8 × 10⁵ U/mg [“low-dose” regimen]), Cpl-1 (3.3 mg; 110 mg/kg; specific activity, 6 × 10⁵ U/mg [“high-dose” regimen]), or CTX (12 mg; 400 mg/kg); control mice received sterile saline. Four hours after injection the animals were killed and blood and peritoneal lavage fluid specimens were processed for determination of bacterial counts. The lower limit of organism quantification in these studies was 10 CFU/ml. For analytical purposes, specimens with <10 CFU/ml were arbitrarily assigned a value of 1 CFU/ml.

Figure 1 and Table 2 summarize the efficacies of the agents in reducing the bacterial loads in the peritoneal lavage fluid and blood after i.p. and i.v. administration of the different agents. At 5 h postchallenge, the bacterial titers in the peritoneal fluid and the blood of the control animals were 7.4 ± 0.6 and 6.5 ± 0.7 log₁₀ CFU/ml, respectively.

The bacterial counts diminished significantly (compared with the counts for the controls) following the i.p. administration of all agents. The most important effect was observed with LytA, although a profound killing effect was also seen after the i.p. administration of Cpl-1 at either the high or the low dose. The mice treated i.p. with CTX experienced the smallest antibacterial effect in the peritoneum. After the i.v. administration of LytA, CTX, or high-dose Cpl-1, the bacterial titers in the peritoneal fluid were significantly diminished compared with those in the controls. LytA administered i.v. had a more potent effect in the peritoneum than either of the two Cpl-1 i.v. regimens.

The i.p. administration of LytA, high-dose Cpl-1, or CTX significantly reduced the bacterial load in the blood; indeed, three of five mice treated with LytA and two of five mice treated with CTX had no detectable bacteremia (Fig. 1). LytA administered i.v. had the greatest bactericidal effect in blood. The antipneumococcal activities of all the agents tested were superior when they were administered i.p. than when they were injected i.v., although the differences were significant only for both doses of Cpl-1 and the bacterial load in peritoneal fluid and blood (P < 0.001) and for LytA and the bacterial load in peritoneal fluid (P < 0.01).

The reduction in the peritoneal and blood colony counts achieved by i.p. LytA treatment reflects the intrinsic activity and bactericidal capacity of LytA. The two Cpl-1 regimens tested were also more effective than CTX when the i.p. route was used. Comparison of the results of the bacterial killing achieved with the i.v. and i.p. routes suggests that LytA is acceptably distributed throughout the circulatory system and enters the peritoneal cavity, which is a highly vascularized site.

To our knowledge, the present study is the first to treat mice with β-lactam-resistant pneumococcal peritonitis-sepsis with LytA. These results may therefore represent a step forward toward the potential use of enzybiotic therapy.

• Open in new tab
• Download powerpoint

FIG. 1.

Antipneumococcal activities in the peritoneal fluid (A and C) and in the blood (B and D) of lytic enzymes or CTX 4 h after administration by the i.p. (A and B) or i.v. (C and D) route in mice with β-lactam-resistant S. pneumoniae peritonitis-sepsis. Each point represents one mouse; five to six animals were included in each group; the mean ± standard deviation for each group is also shown. In panel B, the label 1 indicates that three animals treated with LytA i.p. showed bacterial clearance from the blood and the label 2 indicates that two animals treated with CTX i.p. also showed bacterial clearance from the blood. *, statistically significant difference compared to the results for the control.

• Copyright © 2007 American Society for Microbiology